BioSpace News Archive

Ardelyx, Inc. today announced that it will hold a conference call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time to review second quarter 2022 financial results and provide a business overview.

Mission Bio, Inc. today announced the initial availability of the industry’s first assay capable of determining measurable residual disease (MRD) in cancer down to the level of individual cells, launching a new era for the understanding of disease progression.

Arcadia Biosciences, Inc. today announced that it will release its financial and business results for the second quarter and first half of 2022 after market close on August 11, 2022.

Crown Bioscience , a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.

Prime Medicine, Inc. today announced the expansion of the company’s leadership team with the appointments of the following executives.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2022 and reviewed recent business highlights.

Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit.

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for STAR-0215, which the company is developing for the treatment of Hereditary Angioedema (HAE).

Sunshine Biopharma Inc. today announced that it has agreed to provide additional resources to the University of Arizona R. Ken Coit College of Pharmacy for the purposes of accelerating the development of novel PLpro inhibitors currently underway.

Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network.